MX2007012222A - Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles. - Google Patents
Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.Info
- Publication number
- MX2007012222A MX2007012222A MX2007012222A MX2007012222A MX2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A MX 2007012222 A MX2007012222 A MX 2007012222A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders associated
- immune disorders
- methods
- mutant molecules
- soluble ctla4
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 238000002054 transplantation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 2
- 108010035053 B7-1 Antigen Proteins 0.000 abstract 1
- 102000038504 B7-1 Antigen Human genes 0.000 abstract 1
- 102000007697 B7-2 Antigen Human genes 0.000 abstract 1
- 108010021800 B7-2 Antigen Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66877405P | 2005-04-06 | 2005-04-06 | |
| PCT/US2006/012648 WO2006108035A1 (en) | 2005-04-06 | 2006-04-05 | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007012222A true MX2007012222A (es) | 2007-12-06 |
Family
ID=36694299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007012222A MX2007012222A (es) | 2005-04-06 | 2006-04-05 | Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7482327B2 (https=) |
| EP (1) | EP1868635B1 (https=) |
| JP (1) | JP2008535841A (https=) |
| KR (1) | KR101235484B1 (https=) |
| CN (1) | CN101198347A (https=) |
| AR (1) | AR055052A1 (https=) |
| AU (1) | AU2006231622B2 (https=) |
| BR (1) | BRPI0608144A2 (https=) |
| CA (1) | CA2603970A1 (https=) |
| CY (1) | CY1119145T1 (https=) |
| DK (1) | DK1868635T3 (https=) |
| EA (1) | EA013122B1 (https=) |
| ES (1) | ES2634260T3 (https=) |
| HR (1) | HRP20171121T8 (https=) |
| IL (1) | IL186189A (https=) |
| LT (1) | LT1868635T (https=) |
| ME (1) | ME02930B (https=) |
| MX (1) | MX2007012222A (https=) |
| NO (1) | NO342966B1 (https=) |
| NZ (2) | NZ561655A (https=) |
| PL (1) | PL1868635T3 (https=) |
| PT (1) | PT1868635T (https=) |
| RS (1) | RS56138B1 (https=) |
| SI (1) | SI1868635T1 (https=) |
| WO (1) | WO2006108035A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| JP2008535841A (ja) * | 2005-04-06 | 2008-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法 |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
| EP2612867A1 (en) | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| JP2012500855A (ja) * | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US9738872B2 (en) * | 2008-10-30 | 2017-08-22 | Yeda Research And Development Co. Ltd. | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| US20100297123A1 (en) * | 2009-05-15 | 2010-11-25 | Garrison Fathman C | Combination therapy to inhibit t cell effector function |
| HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| CN103282047B (zh) | 2010-09-08 | 2016-08-24 | 耶达研究及发展有限公司 | 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途 |
| JP2013540731A (ja) | 2010-09-08 | 2013-11-07 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 安定かつ長期間の生着のための免疫抑制薬物組合せ |
| WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| SG11201506919XA (en) | 2013-03-28 | 2015-10-29 | Bristol Myers Squibb Co | Methods for identifying patients at risk for costimulation blockade resistant rejection |
| CN104673822A (zh) * | 2013-11-27 | 2015-06-03 | 深圳先进技术研究院 | 一种重组载体及其制备方法和应用 |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| CN106132429A (zh) | 2014-03-19 | 2016-11-16 | 百时美施贵宝公司 | 使用针对cd40l的域抗体治疗移植物排斥的方法 |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| EP3322424B1 (en) | 2015-07-16 | 2023-10-11 | Yeda Research and Development Co., Ltd. | Use of anti third party central memory t cells |
| ES3064681T3 (en) | 2017-01-18 | 2026-04-28 | Yeda Res And Development Co Ltd | Genetically modified veto cells and use of same in immunotherapy |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| US10286036B2 (en) | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| WO2020010259A1 (en) * | 2018-07-06 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for improving transplant outcomes |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN115089718B (zh) * | 2021-11-30 | 2024-05-28 | 杭州瑞普晨创科技有限公司 | 用于异种移植的免疫抑制剂组合和免疫抑制方法 |
| KR102929448B1 (ko) | 2023-02-03 | 2026-02-26 | 이뮤노바이옴 주식회사 | 이식 거부 반응의 예방 또는 치료용 조성물 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| CA2436139A1 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| US7304033B2 (en) * | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| CA2482042A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| MXPA05006522A (es) | 2002-12-23 | 2006-02-17 | Bristol Myers Squibb Co | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina. |
| MXPA05006523A (es) | 2002-12-23 | 2005-08-26 | Squibb Bristol Myers Co | Procesos de cultivo de celulas de mamiferos para la produccion de proteinas. |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP2008535841A (ja) * | 2005-04-06 | 2008-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法 |
-
2006
- 2006-04-05 JP JP2008505489A patent/JP2008535841A/ja active Pending
- 2006-04-05 EP EP06749324.7A patent/EP1868635B1/en not_active Expired - Lifetime
- 2006-04-05 LT LTEP06749324.7T patent/LT1868635T/lt unknown
- 2006-04-05 SI SI200632175A patent/SI1868635T1/sl unknown
- 2006-04-05 BR BRPI0608144-4A patent/BRPI0608144A2/pt not_active Application Discontinuation
- 2006-04-05 RS RS20170794A patent/RS56138B1/sr unknown
- 2006-04-05 HR HRP20171121TT patent/HRP20171121T8/hr unknown
- 2006-04-05 DK DK06749324.7T patent/DK1868635T3/en active
- 2006-04-05 EA EA200702180A patent/EA013122B1/ru active IP Right Revival
- 2006-04-05 AU AU2006231622A patent/AU2006231622B2/en not_active Expired
- 2006-04-05 ME MEP-2017-162A patent/ME02930B/me unknown
- 2006-04-05 ES ES06749324.7T patent/ES2634260T3/es not_active Expired - Lifetime
- 2006-04-05 PL PL06749324T patent/PL1868635T3/pl unknown
- 2006-04-05 CN CNA2006800198976A patent/CN101198347A/zh active Pending
- 2006-04-05 CA CA002603970A patent/CA2603970A1/en not_active Abandoned
- 2006-04-05 WO PCT/US2006/012648 patent/WO2006108035A1/en not_active Ceased
- 2006-04-05 PT PT67493247T patent/PT1868635T/pt unknown
- 2006-04-05 MX MX2007012222A patent/MX2007012222A/es active IP Right Grant
- 2006-04-05 KR KR1020077025644A patent/KR101235484B1/ko not_active Expired - Lifetime
- 2006-04-05 NZ NZ561655A patent/NZ561655A/en not_active IP Right Cessation
- 2006-04-06 US US11/399,666 patent/US7482327B2/en not_active Expired - Lifetime
- 2006-04-06 AR ARP060101377A patent/AR055052A1/es unknown
-
2007
- 2007-09-23 IL IL186189A patent/IL186189A/en active IP Right Grant
- 2007-10-09 NO NO20075078A patent/NO342966B1/no unknown
-
2008
- 2008-11-19 US US12/313,342 patent/US20100041602A1/en not_active Abandoned
-
2009
- 2009-04-21 NZ NZ576434A patent/NZ576434A/en not_active IP Right Cessation
-
2017
- 2017-07-28 CY CY20171100812T patent/CY1119145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007012222A (es) | Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles. | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| GEP20053658B (en) | Soluble CTLA4 Mutant Molecules and Uses Thereof | |
| PH12020500078A1 (en) | Anti-ctla-4 antibodies and uses thereof | |
| MX344971B (es) | Anticuerpos anti-ctla4 humanizados. | |
| MX2009008918A (es) | Activacion de celulas que presentan antigeno humano a traves de clec-6. | |
| IL184617A (en) | Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody | |
| JO2576B1 (en) | Antibodies | |
| WO2007056539A3 (en) | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy | |
| EP4538295A3 (en) | Antigen binding molecules and methods of use thereof | |
| MX2007001638A (es) | Proteinas de fusion del dominio de unión. | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
| GEP20166454B (en) | Sclerostin binding agents | |
| WO2008094254A3 (en) | Methods and compositions for the treatment of cancer or other diseases | |
| NZ599875A (en) | Human il-23 antigen binding proteins | |
| MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
| TW200602078A (en) | Uses of anti-CTLA-4 antibodies | |
| TW200736275A (en) | Methods and compositions for treating allergic diseases | |
| MX2009009261A (es) | Anticuerpos anti-ip-10 y metodos para su uso. | |
| PL1830881T3 (pl) | Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| SG10201407938TA (en) | Agents for treating disease | |
| WO2010072740A3 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF | |
| WO2007056540A3 (en) | Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |